ERBB2 and breast cancer: In this report, we employ an anti-EGFR MAb IR700 conjugate, panitumumab IR700 (pan IR700), and an anti-HER2 MAb IR700 conjugate, trastuzumab IR700 (tra IR700), to illustrate that combination PIT using EGFR and HER2 as co-targets is selective and effective in targeting such BC in vitro and in vivo.